NCT01675245View on ClinicalTrials.gov

An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade

CompletedOBSERVATIONAL
Enrollment

532

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

No intervention

This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT01675245 - An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade | Biotech Hunter | Biotech Hunter